{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:25:23Z","timestamp":1787498723483,"version":"build-2736575974"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,28]],"date-time":"2023-02-28T00:00:00Z","timestamp":1677542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Selexipag, an oral nonprostanoid prostaglandin receptor agonist, has led to reduced morbidity and mortality in adults with pulmonary arterial hypertension (PAH). While the adult literature has been extrapolated to suggest selexipag as an oral treatment for severe pediatric pulmonary hypertension (PH), longitudinal, multicenter data on the benefits of selexipag in this population are lacking. The purpose of this study is to present a longitudinal, multicentre experience with selexipag in a relatively large cohort of pediatric PH patients and add to the existing selexipag literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>We performed a retrospective, multicenter review describing the clinical outcomes of pediatric PH patients receiving selexipag in addition to standard oral pulmonary vasodilator therapy across three Canadian centers between January 2005 and June 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-four pediatric patients (fifteen female) with a mean age of 9.7 (range 2.0\u201315.5) years were included. Of this cohort, eighteen (75.0%) were in group 1, one (4.2%) was in group 2, four (16.7%) were in group 3, and one (4.2%) was in group 4. Twenty-two (91.7%) patients were on dual PH therapy after six months. Dosing was targeted to achieve 20\u201330\u2005mcg\/kg\/dose orally every twelve hours. Median dose after twelve months was 30\u2005mcg\/kg\/dose. Twelve months following selexipag initiation, median decreases of 0.2\u2005cm in tricuspid annular plane systolic excursion, 3.5\u2005mmHg in right-ventricular systolic pressure, and 6.1\u2005mmHg in mean pulmonary arterial pressure were observed; none of these changes were statistically significant. Three patients died, one clinically deteriorated and required admission to a pediatric intensive care unit, ten had gastrointestinal symptoms, and three had flushing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Selexipag appears to be a safe and effective adjunctive therapy for pediatric PH patients and has a tolerable adverse effect profile aside from gastrointestinal disturbances. Additional prospective studies of changes in hemodynamics and functional classification over a longer period and with a larger sample are needed. Future research should aim to identify subgroups that stand to benefit from the addition of selexipag as well as optimal timing and dosing for the pediatric population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fped.2023.1055158","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T11:50:17Z","timestamp":1678103417000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["A Canadian, retrospective, multicenter experience with selexipag for a heterogeneous group of pediatric pulmonary hypertension patients"],"prefix":"10.3389","volume":"11","author":[{"given":"David","family":"Youssef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Richards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Lague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Vorhies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hosking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Pietrosanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/14656566.2020.1757071","article-title":"An update on the diagnosis and treatment of pediatric pulmonary hypertension","volume":"21","author":"Olgunt\u00fcrk","year":"2020","journal-title":"Expert Opin Pharmacother"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary\u00a0hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1016\/j.jacc.2014.02.575","article-title":"Survival differences in pediatric pulmonary arterial hypertension","volume":"63","author":"Zijlstra","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1183\/09031936.03.00088302","article-title":"Pulmonary arterial hypertension in children","volume":"21","author":"Widlitz","year":"2003","journal-title":"Eur Respir J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2165\/00003495-200767010-00005","article-title":"Therapeutic applications of sildenafil citrate in the management of pediatric pulmonary hypertension","volume":"67","author":"Leibovitch","year":"2017","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/j.1742-1241.2008.01811.x","article-title":"Guidelines for the prevention of central venous catheter-related blood stream infections with prostanoid therapy for pulmonary arterial hypertension","volume":"160","author":"Doran","year":"2008","journal-title":"Int J Clin Pract"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.healun.2010.06.013","article-title":"Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations","volume":"29","author":"Mathier","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1177\/2045893217703369","article-title":"First-in-child use of the oral selective prostacyclin IP receptor agonist selexipag in pulmonary arterial hypertension","volume":"7","author":"Geerdink","year":"2017","journal-title":"Pulm Circ"},{"key":"B11","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1017\/S1047951119001082","article-title":"Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension","volume":"29","author":"Koo","year":"2019","journal-title":"Cardiol Young"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1007\/s00246-017-1677-7","article-title":"Single-center experience using selexipag in a pediatric population","volume":"38","author":"Gallotti","year":"2017","journal-title":"Pediatr Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1017\/S1047951121000937","article-title":"Selexipag use for paediatric pulmonary hypertension: a single centre report focussed on congenital heart disease patients","volume":"31","author":"Lafuente-Romero","year":"2021","journal-title":"Cardiol Young"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2045894018782405","DOI":"10.1177\/2045894018782405","article-title":"Selexipag in three pediatric patients. In: abstracts from the 11th international conference on neonatal and childhood pulmonary vascular disease, 2018; Seattle, WA","volume":"8","author":"Davis","year":"2018","journal-title":"Pulm Circ"},{"key":"B15","year":""},{"key":"B16","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.2147\/DDDT.S103534","article-title":"Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy","volume":"10","author":"Hardin","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.healun.2020.03.029","article-title":"Selexipag for the treatment of children with pulmonary arterial hypertension: first multicenter experience in drug safety and efficacy","volume":"39","author":"Hansmann","year":"2020","journal-title":"J Heart Lung Transplant"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1183\/09031936.00030414","article-title":"Identification of treatment goals in pediatric pulmonary arterial hypertension","volume":"44","author":"Ploegstra","year":"2014","journal-title":"Eur Respir J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2045894018793580","DOI":"10.1177\/2045894018793580","article-title":"Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?","volume":"8","author":"Koestenberger","year":"2018","journal-title":"Pulm Circ"},{"key":"B20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.amjcard.2013.09.032","article-title":"Four- and seven-year outcomes of patients with congenital heart disease-associated pulmonary arterial hypertension (from the REVEAL registry)","volume":"113","author":"Barst","year":"2014","journal-title":"Am J Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2045894019862138","DOI":"10.1177\/2045894019862138","article-title":"Oral treprostinil use in children: a multicenter, observational experience","volume":"9","author":"Kanaan","year":"2019","journal-title":"Pulm\u00a0Circ"},{"key":"B22","doi-asserted-by":"publisher","first-page":"H1235","DOI":"10.1152\/ajpheart.00254.2009","article-title":"Genomewide RNA expression profiling in lung identifies distinct signatures in\u00a0idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension","volume":"298","author":"Rajkumar","year":"2010","journal-title":"Am J Physiol Heart Circ"},{"key":"B23","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1002\/ppul.24687","article-title":"Pulmonary hypertension in children with down syndrome","volume":"56","author":"Bush","year":"2021","journal-title":"Pediatr Pulmonol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1055158\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T11:50:20Z","timestamp":1678103420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2023.1055158\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,28]]},"references-count":23,"alternative-id":["10.3389\/fped.2023.1055158"],"URL":"https:\/\/doi.org\/10.3389\/fped.2023.1055158","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,28]]},"article-number":"1055158"}}